Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a first-in-human, open-label, multicenter Phase 1 study of AT-0174, an investigational oral dual TDO2/IDO1 inhibitor. It is being conducted in adults with advanced solid tumors that have progressed on, or are not suitable for, standard therapy. The main goals are to evaluate the safety and tolerability of AT-0174 and to identify a recommended dose for further study.
Epistemonikos ID: 40a3e648679ae10f1484b1a707ea116250f79e5d
First added on: Oct 22, 2026